The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's Board has recommended a dividend of Rs. 7.55 per equity share (face value Rs. 1) for Financial Year 2025-26, subject to shareholder approval at the ensuing AGM. The record date for dividend eligibility is fixed as July 24, 2026. For FY2026, standalone revenue declined to Rs. 1,05,507 lakhs from Rs. 1,20,009 lakhs in FY2025, while profit after tax fell to Rs. 26,327 lakhs from Rs. 37,296 lakhs (a 29% decline). EPS for FY2026 stands at Rs. 25.17 compared to Rs. 35.65 in the previous year. The auditors issued unmodified opinions on both standalone and consolidated financial results.
The dividend signals shareholder returns despite a significant year-on-year decline in profitability. While the absolute dividend per share is maintained at Rs. 7.55, the lower EPS means a higher payout ratio, which could concern some investors. However, it demonstrates the company's commitment to returning cash to shareholders.